Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 201

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus

Open access
Hasni, Sarfaraz A., Gupta, Sarthak, Davis, Michael, Poncio, Elaine, Temesgen-Oyelakin, Yenealem, Carlucci, Philip M., Wang, Xinghao, Naqi, Mohammad, Playford, Martin P., Goel, Rishi R., Li, Xiaobai, Biehl, Ann J., Ochoa-Navas, Isabel, Manna, Zerai, Shi, Yinghui, Thomas, Donald, Chen, Jinguo, Biancotto, Angélique, Apps, Richard, Cheung, Foo, Kotliarov, Yuri, Babyak, Ashley L., Zhou, Huizhi, Shi, Rongye, Stagliano, Katie, Tsai, Wanxia Li, Vian, Laura, Gazaniga, Nathalia, Giudice, Valentina, Lu, Shajia, Brooks, Stephen R., MacKay, Meggan, Gregersen, Peter, Mehta, Nehal N., Remaley, Alan T., Diamond, Betty, O’Shea, John J., Gadina, Massimo, Kaplan, Mariana J. · 2021 · Nature Communications

Abstract

Increased risk of premature cardiovascular disease (CVD) is well recognized in systemic lupus erythematosus (SLE). Aberrant type I-Interferon (IFN)-neutrophil interactions contribute to this enhanced CVD risk. In lupus animal models, the Janus kinase (JAK) inhibitor tofacitinib improves clinical features, immune dysregulation and vascular dysfunction. We conducted a randomized, double-blind, placebo-controlled clinical trial of tofacitinib in SLE subjects (ClinicalTrials.gov NCT02535689). In this study, 30 subjects are randomized to tofacitinib (5 mg twice daily) or placebo in 2:1 block. The primary outcome of this study is safety and tolerability of tofacitinib. The secondary outcomes include clinical response and mechanistic studies. The tofacitinib is found to be safe in SLE meeting study’s primary endpoint. We also show that tofacitinib improves cardiometabolic and immunologic parameters associated with the premature atherosclerosis in SLE. Tofacitinib improves high-density lipoprotein cholesterol levels (p = 0.0006, CI 95%: 4.12, 13.32) and particle number (p = 0.0008, CI 95%: 1.58, 5.33); lecithin: cholesterol acyltransferase concentration (p = 0.024, CI 95%: 1.1, −26.5), cholesterol efflux capacity (p = 0.08, CI 95%: −0.01, 0.24), improvements in arterial stiffness and endothelium-dependent vasorelaxation and decrease in type I IFN gene signature, low-density granulocytes and circulating NETs. Some of these improvements are more robust in subjects with STAT4 risk allele.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-23361-z

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 201

Metadata

Authors
Hasni, S. A., Gupta, S., Davis, M., Poncio, E., Temesgen-Oyelakin, Y., Carlucci, P. M., Wang, X., Naqi, M., Playford, M. P., Goel, R. R., Li, X., Biehl, A. J., Ochoa-Navas, I., Manna, Z., Shi, Y., Thomas, D., Chen, J., Biancotto, A., Apps, R., Cheung, F., Kotliarov, Y., Babyak, A. L., Zhou, H., Shi, R., Stagliano, K., Tsai, W. L., Vian, L., Gazaniga, N., Giudice, V., Lu, S., Brooks, S. R., MacKay, M., Gregersen, P., Mehta, N. N., Remaley, A. T., Diamond, B., O’Shea, J. J., Gadina, M., & Kaplan, M. J.
Venue
Nature Communications
Published
2021-06-07
Volume
12
Issue
1
Pages
3391-3391
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3170585551
Cited by
201
References
3
FWCI
22.17
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. https://app.cochat.ai/papers/10.1038/s41467-021-23361-z
The paper
Hasni, S. A., Gupta, S., Davis, M., Poncio, E., Temesgen-Oyelakin, Y., Carlucci, P. M., Wang, X., Naqi, M., Playford, M. P., Goel, R. R., Li, X., Biehl, A. J., Ochoa-Navas, I., Manna, Z., Shi, Y., Thomas, D., Chen, J., Biancotto, A., Apps, R., . . . Kaplan, M. J. (2021). Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nature Communications. https://doi.org/10.1038/s41467-021-23361-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.